Aclaris Therapeutics Inc
ACRS
查看详细走势图
3.070USD
-0.070-2.23%
收盘 12/22, 16:00（美东）报价延迟15分钟
332.61M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.23%
5天
-3.15%
1月
+22.31%
6月
+111.72%
今年开始到现在
+23.79%
1年
+12.87%
查看详细走势图
TradingKey Aclaris Therapeutics Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Aclaris Therapeutics Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名69/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.67。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aclaris Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
7.667
目标均价
+133.74%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aclaris Therapeutics Inc亮点
亮点风险
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
业绩增长期
公司处于发展阶段，最新年度总收入18.72M美元
利润高增长
公司净利润处于行业前列，最新年度总收入18.72M美元
估值合理
公司最新PE估值-1.95，处于3年历史合理位
机构减仓
最新机构持股87.21M股，环比减少0.00%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值112.99K
Aclaris Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aclaris Therapeutics Inc简介
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
公司代码ACRS
公司Aclaris Therapeutics Inc
CEOWalker (Neal S)
网址https://www.aclaristx.com/
常见问题
Aclaris Therapeutics Inc(ACRS)的当前股价是多少？
Aclaris Therapeutics Inc(ACRS)的当前股价是 3.070。
Aclaris Therapeutics Inc的股票代码是什么？
Aclaris Therapeutics Inc的股票代码是ACRS。
Aclaris Therapeutics Inc股票的52周最高点是多少？
Aclaris Therapeutics Inc股票的52周最高点是3.475。
Aclaris Therapeutics Inc股票的52周最低点是多少？
Aclaris Therapeutics Inc股票的52周最低点是1.050。
Aclaris Therapeutics Inc的市值是多少？
Aclaris Therapeutics Inc的市值是332.61M。
Aclaris Therapeutics Inc的净利润是多少？
Aclaris Therapeutics Inc的净利润为-132.06M。
现在Aclaris Therapeutics Inc(ACRS)的股票是买入、持有还是卖出？
根据分析师评级，Aclaris Therapeutics Inc(ACRS)的总体评级为买入，目标价格为7.667。
Aclaris Therapeutics Inc(ACRS)股票的每股收益（EPS TTM）是多少
Aclaris Therapeutics Inc(ACRS)股票的每股收益（EPS TTM）是-1.578。
相关品种
